ADMA Biologics Jumps 14% on Zacks Strong Buy Rating

Edgen Stock

·Mar 29 2026, 08:20

Share to

Share to

Copy link

Key Takeaways

ADMA Biologics stock experienced a significant pre-market surge following a 'Strong Buy' rating from Zacks Investment Research, which cited improving earnings estimates. The upgrade signaled growing analyst confidence and triggered substantial investor buying pressure.

Sharp Price Increase: ADMA Biologics shares gapped up 14.2% at the open, jumping from a previous close of $8.29 to an opening price of $9.47.
Positive Catalyst: The move was driven by a recent upgrade to a Zacks Rank #1 (Strong Buy), which followed a 12.9% increase in the consensus earnings estimate for the current year.
Heavy Trading Volume: Investor interest was confirmed by high trading volume, with nearly 7.8 million shares changing hands, indicating strong momentum behind the stock.

Stock Gaps Up 14.2% on Heavy Trading Volume

Shares of ADMA Biologics (NASDAQ: ADMA) opened sharply higher on Friday, gapping up 14.2% as the market opened. The stock, which had closed the previous session at $8.29, began trading at $9.47. The price later settled to $9.2850 on significant trading volume of 7.78 million shares, demonstrating strong investor conviction in the biopharmaceutical company.

Zacks Upgrade Cites 12.9% Rise in Earnings Estimates

The primary catalyst for the stock's performance was its addition to the Zacks Rank #1 (Strong Buy) list on March 23rd. This influential rating followed a notable upward revision in analyst expectations for the company's financial performance. Over the preceding 60 days, the Zacks Consensus Estimate for ADMA's current-year earnings increased by 12.9%. This revision suggests analysts are increasingly confident in the company's ability to generate profits, providing a fundamental basis for the bullish price action.